stockrow
Saturday 7 November 2026
Export GLUE’s income statement to Excel — free account
Monte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024.
- Revenue
- +325.8%
- EPS
- +109.1%
- Free cash flow
- −142.6%
Quarter to September 2026, against a year earlier
10.49
0.24
+2.34%
Follow GLUE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.53 | 38.25 | 85.49 | 17.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(30.28) | (43.97) | (55.67) | (29.64) | |
P/B ratio |
5.59 | 3.15 | 5.04 | 2.45 | |
Price to Tangible BV |
5.59 | 3.15 | 5.04 | 2.45 | |
EV/Sales |
7.48 | 22.74 | 63.87 | 9.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(40.59) | (66.57) | (76.23) | (3.85) | |
EV/FCF |
(33.66) | (49.70) | (57.19) | (3.65) | |
Quick Ratio |
6.05 | 9.44 | 10.49 | 9.31 | |
Current Ratio |
6.12 | 9.54 | 10.58 | 10.32 | |
Net Debt/EBITDA |
7.92 | 13.88 | 13.15 | (2,818.18) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.08 | 0.05 | 0.12 | |
Operating CF/Net income |
0.93 | 0.84 | 1.02 | (13.38) | |
Capex/Depreciation |
(0.37) | (0.92) | (2.47) | (0.73) | |
Research and Development Expense of Revenue |
1,509.49% | 1,046.77% | 534.83% | 83.44% | |
Selling, General and Administrative Expense of Revenue |
378.17% | 241.69% | 113.00% | 20.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
154.94% | 141.31% | 66.57% | 11.63% | |
Graham Net Nets |
0.14 | 0.28 | 0.17 | 0.36 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.93%) | (9.00%) | (7.27%) | (11.74%) | |
Free Cash Flow Yield |
(2.11%) | (1.20%) | (1.31%) | (14.36%) | |
Revenue per Share |
0.03 | 0.04 | 0.09 | 0.53 | |
Operating CF per Share |
(0.52) | (0.37) | (0.43) | (0.40) | |
Capex per Share |
(0.01) | (0.02) | (0.05) | (0.02) | |
Free Cash Flow per Share |
(0.53) | (0.39) | (0.48) | (0.42) | |
Cash per Share |
4.54 | 6.67 | 6.12 | 5.68 | |
Shareholders Equity per Share |
2.81 | 5.23 | 4.80 | 4.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.81 | 5.23 | 4.80 | 4.87 | |
Free Cash Flow |
(43.78) | (39.24) | (48.84) | (42.54) | |
Working Capital |
328.97 | 606.51 | 571.75 | 578.02 | |
Capital Expenditures |
(0.77) | (1.87) | (4.72) | (1.56) | |
Net Current Asset Value |
177.58 | 463.04 | 427.53 | 438.55 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.28 | 0.44 | 0.53 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.89 | 3.01 | 3.65 | — | |
Average Payables |
10.38 | 7.19 | 6.37 | 8.93 | |
Average Assets |
443.70 | 564.81 | 525.37 | 578.78 | |
Average Common Equity |
228.00 | 398.54 | 377.68 | 371.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026